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Transplantation of fetal human ventral mesencephalic (VM) dopaminergic neurons into
the striatum is a promising strategy to compensate for the characteristic dopamine
deficit observed in Parkinson’s disease (PD). This therapeutic approach, however, is
currently limited by the high number of fetuses needed for transplantation and the
poor survival and functional integration of grafted dopaminergic neurons into the host
brain. Accumulating evidence indicates that contrasting inhibitory signals endowed in
the central nervous system (CNS) might support neuronal regeneration. Hence, in the
present study we aimed at improving survival and integration of grafted cells in the host
brain by neutralizing Nogo-A, one of the most potent neurite growth inhibitors in the
CNS. For that purpose, VM tissue cultures were transplanted into rats with a partial
6-hydroxydopamine (6-OHDA) lesion causing a hemi-PD model and concomitantly
treated for 2 weeks with intra-ventricular infusion of neutralizing anti-Nogo-A antibodies.
Motor behavior using the cylinder test was assessed prior to and after transplantation as
functional outcome. At the end of the experimental period the number of dopaminergic
fibers growing into the host brain, the number of surviving dopaminergic neurons in the
grafts as well as graft size was examined. We found that anti-Nogo-A antibody infusion
significantly improved the asymmetrical forelimb use observed after lesions as compared
to controls. Importantly, a significantly three-fold higher dopaminergic fiber outgrowth
from the transplants was detected in the Nogo-A antibody treated group as compared
to controls. Furthermore, Nogo-A neutralization showed a tendency for increased
survival of dopaminergic neurons (by two-fold) in the grafts. No significant differences
were observed for graft volume and the number of dopaminergic neurons co-expressing
G-protein-coupled inward rectifier potassium channel subunit two between groups. In
sum, our findings support the view that neutralization of Nogo-A in the host brain
may offer a novel and therapeutically meaningful intervention for cell transplantation
approaches in PD.
Keywords: Parkinson’s disease, Nogo-A, cell transplantation, dopaminergic neurons, behavior, rat
Abbreviations: 6-OHDA, 6-hydroxydopamine; CNS, central nervous system; GIRK2, G-protein-coupled inward rectifier
potassium channel subunit 2; i.p., intraperitoneal; LINGO-1, leucine rich repeat neuronal protein 1; NgR1, Nogo-receptor 1;
PBS, phosphate buffered saline; PD, Parkinson’s disease; s.c., subcutaneous; SNc, substantia nigra pars compacta; TH, tyrosine
hydroxylase; VM, ventral mesencephalic.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
mainly characterized by the progressive loss of dopaminergic
neurons in the substantia nigra pars compacta (SNc) with
a subsequent loss of dopamine innervation in the striatum.
To restore the imbalanced innervation in the striatum, cell
replacement strategies have been evaluated as a long-term
treatment for PD. Numerous clinical trials showed functional
improvement after transplantation of fetal human ventral
mesencephalic (VM) dopaminergic neurons into the striatum
of PD patients (Lindvall et al., 1989, 1990; Kordower et al.,
1995; Hauser et al., 1999) even without the support of
additional pharmacological treatment (Kefalopoulou et al.,
2014). It became clear, however, that before cell replacement
strategies can be used in clinical practice, the criteria for
patient selection (Freed et al., 2001; Barker et al., 2013) as
well as the collection, the pre-treatment and the storage of
donor tissue have to be optimized and standardized (Petit
et al., 2014). Currently, a multicenter clinical trial called
TRANSEURO is establishing a standardized protocol for
transplantation approaches in PD (Moore et al., 2014). Two
other major limitations associated with cell transplantation
procedures in PD still include suboptimal survival and poor
innervation of the host brain by grafted dopaminergic neurons.
Several transplantation studies in animals revealed that most
of the transplanted dopaminergic neurons die within the first
week after transplantation and that many of the surviving
dopaminergic neurons do not functionally integrate into the
host brain (Emgard et al., 1999; Karlsson et al., 2000). In
line with this notion, it has been shown that mainly the
dopaminergic sub-population expressing the G-protein-coupled
inward rectifier potassium channel subunit 2 (GIRK2) innervate
the host brain after transplantation (Mendez et al., 2005;
Thompson et al., 2005; Gaillard et al., 2009; Grealish et al.,
2010).
Accumulating evidence points out that the tissue
microenvironment plays a vital role in influencing the degree
of engraftment of the transplant (Ourednik and Ourednik,
2005; Alsberg et al., 2006; Stefanova et al., 2009). Suppression
of myelin associated proteins like Nogo-A, a major neurite
growth inhibitor in the central nervous system (CNS) might
therefore offer novel ways to improve functional recovery
in various disease states. In line with this notion, several
studies have demonstrated that neutralizing Nogo-A signaling
with anti-Nogo-A antibodies promoted axonal sprouting as
well as improved functional recovery in spinal cord injured
rats and monkeys (Merkler et al., 2001; Freund et al., 2009).
Moreover, Nogo-A antibodies increased neuronal remodeling
and functional recovery after stroke in rodents (Cheatwood
et al., 2008; Tsai et al., 2011). Hence, we hypothesized that this
strategy may be considered a valuable approach in the context
of cell transplantation in PD. Nogo-A, is widely distributed
in the CNS and it is expressed in dopaminergic neurons of
the rodent fetus as well as in dopaminergic neurons of the
adult rodent SNc (Seiler et al., 2013; Kurowska et al., 2014;
Schawkat et al., 2015). Notably, knock-out animals for leucine
rich repeat neuronal protein 1 (LINGO-1), a co-receptor of the
Nogo-receptor 1 (NgR1) complex, showed increased survival
of dopaminergic neurons and functional improvements after
induction of parkinsonian symptoms (Inoue et al., 2007).
In line with this study, antagonizing the NgR1 significantly
increased dopaminergic cell numbers and their morphological
complexity in primary VM cultures (Seiler et al., 2013).
Therefore, in the present work, we investigated the potential of
Nogo-A neutralization on graft survival and function in a rat
model with induced parkinsonian symptoms. We demonstrate
here that neutralization of Nogo-A significantly promoted
sprouting of grafted dopaminergic cells into the host brain
and led to robust functional improvement of asymmetric
forelimb use. Our results support the concept of Nogo-A
inhibition as a relevant strategy for transplantation approaches
in PD.
MATERIALS AND METHODS
Animals
FemaleWistar rats (Janvierlabs, France) were housed at 12 h light
dark cycle with food and water ad libitum. For the preparation
of the transplants, pregnant Wistar rats were purchased from
Janvier Labs (France). All experiments were carried out in the
light phase and in accordance with the guidelines of the Animal
Research Ethics Committee of the Canton Berne, Switzerland,
and the University of Bern Animal Care and Use Committee,
Switzerland.
Experimental Design
To induce a unilateral reduction of dopaminergic neurons
in the substantia nigra, animals received 6-hydroxydopamine
(6-OHDA) injections into the right striatum. Six weeks after
the lesion, each rat was grafted with half a fetal ventral
mesencephalon transplant into the right striatum and received
a mini-osmotic pump that injected Nogo-A neutralizing
antibodies 11C7 or control antibodies (IgG; kind gifts from
Dr. Anis Mir, Novartis, Switzerland) over a period of 2 weeks
into the right lateral ventricle. Six weeks after the transplantation
the rats were perfused and their brains used for histological
analyses. Behavior (cylinder test) of the rats was assessed
1 week before (baseline) and 5 weeks after the lesion
(lesioned) and 1, 3 and 5 weeks after the transplantation
(Figure 1).
Parkinson’s Disease Rat Model
Female Wistar rats (200–270 g; Janvierlabs, France) were
anesthetized with Isoflurane (75% N2O, 20% O2, 4.5–5%)
followed by an intraperitoneal (i.p.) injection of Narketan
(75 mg/kg; Vétoquind AG, Ittigen, CH, Switzerland) and
Xylaxine (5 mg/kg; Vétoquind AG, Ittigen, CH, Switzerland)
and a subcutaneous (s.c.) injection of Buprenorphine (0.5 mg/kg;
Reckitt Benckiser AG, Wallisellen, Switzerland) applied 30 min
before surgical intervention. Thereafter, the rats were placed in
a stereoscopic frame (Stoelting Co.) on a heating pad. Each rat
received an injection of 4 µl of 6-OHDA (20 mM 6-OHDA;
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FIGURE 1 | Experimental design of the study. Rats received a unilateral
intra-striatal 6-hydroxydopamine (6-OHDA) injection (lesion) and 6 weeks later
the animals were transplanted with ventral mesencephalic (VM) free-floating
roller-tube cultures (Tx). Concomitantly, rats were implanted with mini-osmotic
pumps releasing neutralizing Nogo-A antibodies (11C7) or control antibodies
(IgG) for a period of 2 weeks (black box). Six weeks after the transplantation
the rats were perfused (perfusion) and their brains removed for histological
analyses. Behavior by means of the cylinder test was assessed 1 week before
the lesion (behavior baseline), 5 weeks after the lesion (behavior lesioned) and
1, 3 and 5 weeks after the transplantation (behavior 1 Wp.T.; behavior
3 Wp.T.; behavior 5 Wp.T.).
H116 Sigma-Aldrich Chemie GmbH) through a small burr
hole created in the skull into the right striatum. The injection
was performed over 4 min using a 10 µl Hamilton syringe.
The following coordinates in relation to bregma were used
(PaxinosWatson rat brain atlas): anterior 1.0 mm, lateral 3.0 mm
and 5.0 mm ventral to the dura, the incisor bar was set at
0.0 mm. After the surgery rats were allowed to recover for
5 weeks.
Preparation of Transplants
The organotypic fetal rat VM free-floating roller-tube culture
technique was used for the preparation of the grafts as previously
described (Andereggen et al., 2009). In brief, pregnant Wistar
rats were anesthetized with Isoflurane (75% N2O, 20% O2,
4.5–5%) followed by an i.p. injection of Narketan (120 mg/kg)
and Xylaxine (20 mg/kg). After removal of the fetus by cesarean
section, the ventral mesencephalon was dissected out of the
fetal brain with the help of a stereoscopic microscope, cut
into four equally sized pieces corresponding to two rostral
and two caudal portions and individually placed into gas-
permeable conical plastic tubes (Falcon), supplied with 1 ml
of culture medium consisting of 55% DMEM, 32.5% Hank’s
balanced salt solution (HBSS; Gibco), 0.3% glucose, 10% fetal
calf serum (FCS; Gibco) and 1% 0.01 M HEPES (Merck)
as well as antibiotics/antimycotics (No. 061-05240 D; Gibco).
Thereafter, the tubes were placed into a roller drum and
grown for 7 days in an incubator at 37◦C in a 5% CO2
atmosphere as described in detail previously (Spenger et al.,
1994). The medium was changed after 2 and 5 days in
vitro.
Transplantation
Six weeks after the intrastriatal 6-OHDA lesions rats were
anesthetized with Isoflurane (75% N2O, 20% O2, 4.5–5%)
followed by an i.p. injection of Narketan (75mg/kg) and Xylaxine
(5 mg/kg). A s.c. injection of Buprenorphine (0.5 mg/kg) was
given 30 min before the operations. Thereafter, the rats were
mounted on a stereoscopic frame on a heating pad. Each rat
received an intrastriatal graft consisting of one rostral and one
caudal VM free-floating roller tube culture corresponding to half
of a ventral mesencephalon from one embryo to assure roughly
equal amounts of dopaminergic neurons in the grafts. The
following coordinates in relation to bregma (Paxinos Watson
rat brain atlas) were used: anterior 1.0 mm, lateral 2.7 mm
and 4.5 mm ventral to the dura, the incisor bar was set at
0.0 mm. After the transplantation procedure, mini-osmotic
pumps (2 ml2, Alzet osmotic pumps, DURECT Corporation
ALZET Osmotic Pumps) were implanted under the skin and
the cannulas subcutaneously connected to the skull into the
right ventricle of each rat (Alzet brain infusion kit2), according
to the following coordinates in relation to bregma (Paxinos
Watson rat brain atlas): posterior 0.8 mm, lateral 1.6 mm and
3.5 mm ventral to the dura, the incisor bar was set at 0.0 mm.
The mini-osmotic pumps were filled with either monoclonal
mouse Nogo-A antibodies (11C7; 1 mg/ml) or control mouse
IgG (1 mg/ml) and administered these substances continuously
during the following 2 weeks (flow rate: 5 µg/h). The animals
were randomly assigned to the two groups (n = 5 for each group)
and let to recover for 1 week.
Cylinder Test
To analyze the asymmetry in forelimb use, as observed after
unilateral lesions, the cylinder test is a reliable measure for
analysis of 6-OHDA induced behavioral changes in animal
models of PD (Brooks and Dunnett, 2009; Cordeiro et al., 2010;
Schaar et al., 2010). Behavior was assessed 1 week before the
lesion (baseline), 5 weeks after the lesion (lesioned) and 1, 3
and 5 weeks after the transplantation (1 Wp.T., 3 Wp.T. and
5 Wp.T., respectively). In brief, rats were placed in a transparent
cylinder (diameter 30 cm and height 41 cm) and were video
recorded for 10 min. Mirrors were placed behind the cylinder
to allow a 360◦ view on the cylinder walls. The number of wall
touches with the left, the right or both paws together was counted
by a researcher blinded to the treatment groups. In order to
discriminate between a meaningful physiological movement and
an accidental touch, only contacts in which the rat supported
its body weight on the forelimb with extended digits were
counted. Furthermore, rats that touched the wall less than
20 times during the 10 min period were excluded from the
analysis (Schallert et al., 2000; lesioned: one animal from the
IgG group with 16 touches; 1 Wp.T.: one animal from the 11C7
group with 13 touches; 3 Wp.T.: one animal from the 11C7
group with 13 touches; 5 Wp.T.: one animal from the IgG group
with 14 touches and one animal from the 11C7 group with
14 touches). The percentage of left wall touches are calculated
according to the formula: [(left + 12 of both paw touches)/(left +
right + both paw touches)] ∗ 100 as previously described (Boix
et al., 2015).
Perfusions
Six weeks after the transplantation, the rats were anesthetized
with Isoflurane (75% N2O, 20% O2, 4.5–5%) followed by an
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i.p. injection of Narketan (75 mg/kg) and Xylaxine (5 mg/kg).
Just prior to opening the thorax the rats received an i.p.
injection of Fentanyl (0.005mg/kg, Janssen-AG, Zug, CH,
Switzerland). Thereafter, the rats were transcardinally perfused
with 200 ml ice cold 0.1M phosphate buffer saline (PBS, pH 7.4)
containing heparin (1000 I.E./100 ml, NOVO Nordisk) followed
by 250 ml 4% paraformaldehyde in 0.1M PBS. The brains were
removed from the skull and placed in 4% paraformaldehyde
overnight and thereafter cryoprotected in 10% sucrose-PBS
solution.
Immunohistochemistry
The brains were cut on a cryostat (Leica CM 1900) into
30 µm thick coronal slices and mounted on Superfrost slides
(Thermo Scientific) so that on one slide 3 brain slices were
mounted (one 180 µm apart from the next one). Brain
sections were washed 4× in PBS and blocked with 10%
horse serum in 0.1% Triton-PBS. Primary and secondary
antibodies were incubated in a 0.1% Triton-PBS solution
containing 2.5% horse serum. After overnight incubation
with the mouse monoclonal anti-tyrosine hydroxylase (TH)
antibody (1:1000, Millipore) and/or the polyclonal rabbit anti-
GIRK2 antibody (1:200, Alomone), the selected sections were
washed 4× in PBS and incubated for 2 h with a secondary
biotinylated anti-mouse IgG (1:200, Vector Laboratories)
antibody. Subsequently, the slides for the TH staining only
were washed in PBS, incubated in a solution of 10% methanol
and 3% hydrogenperoxide in PBS to block the endogenous
peroxidase and washed again in PBS. Following incubation with
an avidin-biotin-complex (7 µl/ml; Vectastain ABC-Peroxidase
KIT, Vector Labs) for 1 h, specifically bound antibodies were
visualized with a metal-enhanced 3, 3′-diaminobenzidine
substrate kit (Pierce, 34002, Life Technologies). Sections were
dehydrated in alcohol, cleared in xylene and mounted in
Eukitt (O. Kindler GmbH, Freiburg, Germany). The slides
for the TH/GIRK2 co-localization analyses were washed 4×
with PBS and incubated for 2 h with the Alexa-Fluor 594
nm donkey conjugated anti-mouse IgG (1:250, Molecular
Probes) and the Alexa-Fluor 488 nm donkey conjugated
anti-rabbit IgG (1:250, Molecular Probes) antibodies. Cell
nuclei were counterstained with Hoechst 33342 (Invitrogen,
Molecular Probes) at 1:10,000. Thereafter, the sections were
washed in PBS 4 × 10 min and covered with 50% PBS-
glycerol mounting media. Fluorescence pictures were taken
using a Zeiss Laser scanning confocal microscope (LSM 710).
Brightness, saturation, and sharpness of presented images were
adjusted only as necessary to best replicate the immunostaining
as viewed directly under the microscope (Gombash et al.,
2012).
Histological Analyses
All analyses were done by a researcher blinded to the treatment
groups using a calibrated neuron tracing software (Cellsense
Dimension, Olympus) and a microscope (Olypmus DP72)
equipped with a motorized stage that was connected to a digital
camera (Olympus).
Estimation of TH Positive Cells in the SNc
The estimation of the extent of the lesion was done as
described previously by Tronci et al. (2012). In brief, brain
sections of each animal were selected corresponding to the
following coordinates in relation to bregma (Paxinos Watson
rat brain atlas): posterior 4.8 mm (three sections analyzed,
range 4.7–4.9 mm), 5.3 mm (three sections analyzed, range
5.2–5.4 mm), and 5.8 mm (three sections analyzed, range
5.7–5.9 mm). TH positive cells were counted in the SNc of the
lesioned as well as the unlesioned according to stereological
methods (assisted by S.A. Tschanz, Microscopy Imaging Center,
Institute of Anatomy, University of Bern, Switzerland) with
the help of a microscope (Olypmus DP72) equipped with
a motorized stage that was connected to a digital camera
(Olympus). TH positive cells with a clearly stained cell body were
counted at 20× magnification excluding the cells touching the
right and lower boarder of the frames. Data are expressed as
percentage of TH positive cells on the lesioned side as compared
to the number of TH positive neurons on the unlesioned
side.
Histological Analysis of the Graft
Every third section containing a graft was chosen by systematic
randomized sampling to determine the size of the graft, the
number of TH positive fibers growing 100 µm into the host
brain and the number of surviving TH positive cells in the
graft. The volume of the graft was calculated as previously
described (Andereggen et al., 2009). In brief, graft boundaries
were traced using a calibrated neuron tracing software (Cellsense
Dimension, Olympus) and after automated computation of
the areas integrated to yield the graft volume. Assessment of
TH positive fibers growing into the host brain was done as
previously described by Andereggen et al. (2009). In brief, TH
positive fibers originating in the graft were followed up to a
virtual line drawn 100 µm from the graft boundary with a
length of 300 µm and counted if they crossed this line. The
counts were done at four sites, i.e., medial, lateral, dorsal and
ventral from the border of the graft using a 10× magnification.
The number of TH positive cells throughout the grafts was
counted according to stereological methods (assisted by S.A.
Tschanz, Microscopy Imaging Center, Institute of Anatomy,
University of Bern, Switzerland) with the help of a microscope
(Olypmus DP72) equipped with a motorized stage that was
connected to a digital camera (Olympus). The cells were counted
at 20× magnification excluding the ones touching the right
and lower boarder of the frames. Only cells with a distinct
immunoreactivity and a clear neuronal shape were included for
analysis. The co-localization rate of TH positive neurons with
GIRK2 was analyzed as described previously (Andereggen et al.,
2009). In brief, the most central slides containing three brain
sections of each graft were selected and stained for TH and
GIRK2. The analysis was done with the help of a microscope
(Olypmus DP72) equipped with a motorized stage that was
connected to a digital camera (Olympus) at 20× magnification
excluding the cells touching the right and lower boarder of the
frames and only positive cells with a clear immunoreactivity
and a clear neuronal shape were chosen for co-localization
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analyses. Data are expressed as percentage of total TH positive
cell numbers.
Estimation of TH Positive Fibers in the Striatum
The density of TH positive fibers in the striatum was assessed
as described previously with slight modifications (Winkler et al.,
1996; Hoglinger et al., 2001). In brief, pictures of the lesioned
and unlesioned dorsal striatum, 540 µm rostral before the
first graft was detected, were taken from all animals with the
help of a microscope (Olypmus DP72) that was connected
to a digital camera (Olympus). The pictures were converted
to 8 bit black and white images and inverted using the Fiji
software. The mean gray intensity of the dorsal striatum of the
lesioned and unlesioned side was measured in a defined area
(100,000µm2). To account for non-specific background staining,
the mean gray value in a defined area (30,000 µm2) in the
corpus callosum was measured. First the mean gray intensity
of the corpus callosum was substracted form the respective
striatal mean gray intensity values. Thereafter the values of the
lesioned striatum were expressed as percentage of the unlesioned
side.
Statistical Analysis
For statistical analysis a commercially available software package
was used (GraphPad Prism 6). To compare group means of
several groups repeated two-way analysis of variance (ANOVA)
was used, followed by Tukey’s or Bonferroni’s multiple
comparison test where appropriate. Statistical significance of
two groups only, was assessed by two-tailed unpaired t-test and
the statistical significance levels are expressed as tα/υ , where
α indicates the student’s t values and υ the relative degree of
freedom. Statistical significance was set at p < 0.05. Data are
presented as mean± SEM.
RESULTS
Estimated Extent of the Lesion
To determine the extent of the lesion, the surviving TH positive
cells in the SNc of each rat were counted. As anticipated our
lesions corresponded to an early stage of PD (Figure 2). Loss
of TH positive neurons was 34.2 ± 3.0% on the lesioned side
as compared to unlesioned control side with no differences
observed for the three different levels analyzed in relation to
bregma (34.2± 4.3%, 32.1± 4.6% and 32.9± 5.1%, for−4.8mm,
−5.3 mm and−5.8 mm, respectively).
Behavioral Analysis
To determine the asymmetry in forelimb use, we analyzed the
rat’s behavior in the cylinder test. As expected, after the lesion
the rats used the left paw (contralateral to the lesion) to touch the
wall significantly less often as compared to baseline (46.0± 3.2 vs.
19.2 ± 7.8, % of left paw use for baseline and lesioned in the IgG
group, t3.2/6 ≤ 0.05 and 52.9 ± 2.3 vs. 30.1 ± 4.7, % of left paw
use for baseline and lesioned in the 11C7 group, t4.4/8 ≤ 0.01;
Figure 3A). No significant difference was found between the
11C7 and the IgG groups (data not shown). One week after
FIGURE 2 | Extent of the 6-OHDA lesion on tyrosine hydroxylase (TH)
positive cell numbers in the substantia nigra. 6-OHDA was injected into
the right striatum at the following coordinates in relation to bregma (Paxinos
Watson rat brain atlas): anterior 1.0 mm, lateral 3.0 mm and 5.0 mm ventral to
the dura (A). Representative photomicrographs showing TH positive neurons
on the control and lesion (*) sides of the substantia nigra (B). Boxed areas in
(B) are shown at higher magnification (C1,C2). Scale bars: 1 mm (B) and
200 µm (C1,C2).
the transplantation no significant improvement in using the left
paw in either one of the treatment groups could be observed
as compared to after the lesion (19.2 ± 7.9 vs. 25.9 ± 7.5 and
30.1 ± 4.7 vs. 31.7 ± 5.8, % of left paw use for lesioned, IgG
and 11C7, respectively; Time point, F(2,14) = 25.48, p < 0.0001;
post hoc, lesioned vs. IgG p = 0.47 and lesioned vs. 11C7
p = 0.94; Figure 3A). Similarly, 3 weeks after the transplantation
no significant improvement in either one of the treatment
groups could be detected as compared to after the lesion
(19.2 ± 7.9 vs. 31.8 ± 7.0 and 27.2 ± 4.7 vs. 40.2 ± 7.9, %
of left paw use for lesioned, IgG and 11C7, respectively; Time
point, F(2,12) = 21.74, p = 0.0001; post hoc, lesioned vs. IgG
p = 0.12 and lesioned vs. 11C7 p = 0.09; Figure 3B). Importantly,
5 weeks after the transplantation the asymmetrical forelimb use
was significantly improved in the 11C7 treated rats compared to
after the lesions (19.2 ± 7.8 vs. 24.2 ± 6.5 and 32.8 ± 4.9 vs.
44.8 ± 3.0, % of left paw use for lesioned, IgG and 11C7,
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FIGURE 3 | Behavioral assessment of IgG or 11C7 treated rats by
means of the cylinder test. The outcome is shown before and after the
6-OHDA lesion as well as one (1 W.p.T.) (A), three (3 W.p.T.) (B) and 5 weeks
after the transplantation (5 W.p.T.) (C). The 6-OHDA lesion resulted in
significantly lower wall touches with the left paw (A–C). Notably, the 11C7
treatment improved asymmetrical forelimb use 5 Wp.T as compared to after
the lesion. (C). In addition, 11C7 treated rats performed better than IgG
treated rats 5 Wp.T. (C). In contrast, IgG treated rats did not improve their
behavior (A–C). Data are given as mean ± SEM and expressed as percentage
of corresponding baselines. *p < 0.05 vs. corresponding baselines IgG,
**p < 0.05 vs. corresponding baselines 11C7, #p < 0.05 vs. corresponding
lesion 11C7.
respectively; Time point, F(2,12) = 29.04, p < 0.0001; post hoc,
lesioned vs. IgG p = 0.53 and lesioned vs. 11C7 p = 0.05).
Moreover, the 11C7 treated rats showed a trend towardsmore left
paw uses compared to IgG treated rats (24.2± 6.5 vs. 44.8± 3.0,
% of left paw use for IgG and 11C7, respectively; Treatment,
F(1,6) = 5.534, p = 0.057; post hoc, IgG vs. 11C7 p < 0.05;
Figure 3C). In contrast, the IgG treated rats never performed
significantly better during the observed test period than after the
lesion and showed no recovery as compared to baseline levels
(Figures 3A–C).
Histological Analysis of the Grafts
Both groups of treated rats showed surviving grafts that did not
differ significantly in their volume (t0.8/8 = 0.448; Figure 4).
Notably, 11C7 treatment significantly increased the number of
TH positive fibers growing 100 µm into the host brain as
compared to the IgG group (by 2.9 fold; t2.4/8 ≤ 0.05; Figure 5).
Similarly, 11C7 treatment resulted in increased densities of
TH positive cells in the grafts as compared to the IgG group
(by 2.4 fold; t1.2/8 = 0.258) which, however, did not reach
statistical significance (Figure 6). Moreover, to determine the
sub-population of dopaminergic neurons that has been shown
to integrate best into the host brain after transplantation, we
investigated the percentage of grafted TH positive neurons
co-localizing with GIRK2. The analysis revealed that about
75% of the grafted TH positive neurons co-expressed GIRK2,
however, no significant differences were detected between groups
(Figure 7).
Estimation of TH Positive Fibers in the
Striatum
To evaluate a potential effect of anti-Nogo-A antibody treatment
on endogenous fiber growth of the surviving dopaminergic
neurons, the TH positive fiber density in the dorsal striatum
was analyzed. The densiometric analysis revealed, however, no
difference of the mean gray intensity of TH positive fibers in
the striatum of IgG and 11C7 treated rats (76.8 ± 18.9 vs.
62.7 ± 15.0, % of unlesioned side, IgG and 11C7, respectively;
t0.6/7 = 0.573; Figure 8).
DISCUSSION
The present study shows for the first time, that transplantation
of fetal VM neurons into the striatum of lesioned hemi-
parkinsonian rats with concomitant neutralizing Nogo-A
antibody treatment significantly increased graft derived
dopaminergic fiber outgrowth and resulted in functional
recovery.
In the present study, the rats were transplanted with only
half a ventral mesencephalon, which corresponds to a sub-
therapeutic treatment, since we have previously shown that
transplantation of a whole ventral mesencephalon results in
complete recovery (Meyer et al., 1998). We have chosen to
transplant organotypic free-floating roller tube cultures as this
method allows for effective storage of midbrain tissue, which
is of importance in clinical settings where several fetuses have
to be pooled to reach the amount of dopaminergic neurons
needed for successful transplantations (Meyer et al., 1998; Studer,
2001). The observed lack of functional improvement after IgG
treatment is thus not surprising and is consistent with our
previously published data (Sautter et al., 1998; Matarredona et al.,
2003). In contrast, neutralizing Nogo-A antibody treatment in
a time dependent manner reversed the asymmetrical forelimb
use induced by the 6-OHDA lesions over the observed period
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FIGURE 4 | Effects of intra-ventricular infusion of IgG or 11C7 on graft volumes. Representative photomicrographs of grafts treated with IgG or 11C7 stained
for TH. The graft boarder is highlighted with a dashed black line. Scale bar: 200 µm. No difference in graft volume was found between the two treatment groups, as
demonstrated in the bar graph. Data are given as mean ± SEM and are presented as percentage of control (IgG).
FIGURE 5 | Effects of intra-ventricular infusion of IgG or 11C7 on TH positive fiber outgrowth. TH positive fibers from the grafts growing into the host brain
(arrows) are shown on representative photomicrographs from IgG (left panel) and 11C7 (middle panel) treated animals. The black dashed line indicates the graft
boarder. Scale bar: 20 µm. Note that 11C7 treatment resulted in a significantly increased number of TH positive fibers growing 100 µm into the host brain, as shown
in the bar graph (right panel). Data are given as mean ± SEM and are presented as percentage of control (IgG). ∗p < 0.05.
FIGURE 6 | Effects of intra-ventricular infusion of IgG or 11C7 on TH positive cell numbers in the grafts. Representative photomicrographs showing TH
positive cells (in red) in grafts from IgG and 11C7 treated animals. The sections were co-stained for the nuclear marker Hoechst (blue). Scale bar: 100 µm. Note that
11C7 treated grafts revealed a tendency towards higher numbers of TH positive cells in the graft, as shown in the bar graph. Data are given as mean ± SEM and are
presented as percentage of control (IgG).
of 5 weeks. Even though we observed a roughly two fold higher
survival of dopaminergic cell numbers in the graft of animals
treated with neutralizing Nogo-A antibodies as compared to
controls this difference did not reach statistical significance.
We hence inferred that behavioral recovery was likely not
due specifically to an increased survival of grafted DAergic
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FIGURE 7 | Effects of intra-ventricular infusion of IgG or 11C7 on TH positive cells co-localizing with G-protein-coupled inward rectifier potassium
channel subunit 2 (GIRK2) in the grafts. Representative photomicrographs showing TH positive (red) and GIRK2 positive (green) cells in grafts from IgG and 11C7
treated animals. The sections were co-stained for the nuclear marker Hoechst (blue). Selected TH positive cells co-localizing with GIRK2 are highlighted with white
arrows. Scale bar: 100 µm. No significant difference in number of TH positive cells co-expressing GIRK2 was observed between the two treatments, as
demonstrated in the bar graph. Data are given as mean ± SEM and are presented as percentage of TH positive cells.
FIGURE 8 | Effects of intra-ventricular infusion of IgG or 11C7 on TH positive fibers in the dorsolateral striatum. Representative photomicrographs
showing TH positive fibers in the dorsolateral striatum on the control and lesion sides from IgG and 11C7 treated animals. Scale bar: 100 µm. No significant
difference in the TH positive fiber density was observed between the two treatments.
neurons. This finding is somewhat surprising as Inoue et al.
(2007) demonstrated that inhibition of LINGO-1 increases
the survival of DAergic neurons in a mouse model of PD.
Furthermore, blocking NgR1 or LINGO-1 was demonstrated
to significantly increase the number of dopaminergic neurons
in midbrain cultures (Inoue et al., 2007; Seiler et al., 2013).
The difference in the outcome between our present study
and the study by Inoue et al. (2007) may be due to the
diverse signaling mechanisms of Nogo-A. While inhibition
of LINGO-1 interferes directly with the NgR1, anti-Nogo-
A antibodies target the B-20 domain of Nogo-A, thus a
structure that signals independent of NgR1 (Kurowska et al.,
2014). In both groups of animals, a substantial portion of
surviving dopaminergic cells in the grafts co-expressed GIRK2,
however, no difference was detected between groups hinting
to the idea that Nogo-A neutralization did not favor a specific
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subpopulation of grafted neurons. Nevertheless, given the
tendency for higher numbers of dopaminergic neurons in the
Nogo-A group of animals one may assume that overall a larger
portion of dopaminergic neurons of the GIRK2 phenotype are
present in this grafts. Because graft size did not differ significantly
between control and anti-Nogo-A treated rats, we suggest
that the anti-Nogo-A promoted graft-derived dopaminergic
fiber outgrowth contributed primarily to functional recovery.
This hypothesis is supported by the observations from other
studies demonstrating functional recovery in absence of higher
survival of grafted dopaminergic neurons but in presence of
increased fiber outgrowth and integration (Haque et al., 1996;
Zhou et al., 1997; Yurek et al., 1998). Moreover, our results
showing no difference of the fiber density in the striatum
between both treatment groups supports the idea that mainly
the fiber outgrowth of the transplanted dopaminergic neurons
contributed to the improved behavior. Nevertheless, we cannot
exclude that the treatment with anti-Nogo-A antibodies only
accelerates the fiber outgrowth of the transplanted dopaminergic
neurons. Whether at later time points the IgG treated rats
would display increased densities of TH fibers sprouting
from the graft remains to be investigated. Moreover, we
cannot rule out the possibility that the graft itself influenced
endogenous sprouting of remaining TH positive fibers, as several
groups have reported particularly with adrenal gland tissue
(Bankiewicz et al., 1990; Kordower et al., 1991) Promoting
integration rather than the survival of grafted dopaminergic
cells might be the relevant strategy to improve efficacy of
transplants. Even though our study did not specifically address
for adverse effects associated with the application of neutralizing
Nogo-A antibodies we did not observe any obvious changes
in the behavior of the animals. Given that it has been
demonstrated that intra-ventricular administration of anti-
Nogo-A antibodies leads to a widespread distribution of the
antibodies in the brain (Wiessner et al., 2003) possible side
effects of an intra-ventricular administration of anti-Nogo-A
antibodies cannot completely be excluded. Nevertheless, a similar
injection route, namely intrathecal administration of anti-
Nogo-A antibodies in spinal cord injured patients, has been
demonstrated to be feasible and safe (Zörner and Schwab,
2010).
Our findings showing augmented fiber outgrowth after
Nogo-A neutralization, are in contrast to previous reports,
showing unchanged neurite length and even decreased
neurite numbers in dopaminergic neurons from Nogo-A
knock-out animals (Kurowska et al., 2014). It is, however,
important to note that the outcome of experiments employing
Nogo-A knock-out animals differs from those using Nogo-A
neutralization experiments. It has been reported that Nogo
gene knockout results in inferior regeneration capacity as
compared to treatment of animals with neutralizing agents
(Teng and Tang, 2005). The authors proposed that these
differences may be explained by the potential interactions of
Nogo-A with other molecules, which do not take place in
knock-out animals (Teng and Tang, 2005). In this respect,
interactions between Nogo-A and neurotrophic factors
(Raiker et al., 2010; Sepe et al., 2014) are of particular
interest in view of cell transplantation approaches for PD,
as glial cell line-derived neurotrophic factor, brain-derived
neurotrophic factor and nerve growth factor have been
described to improve graft functions and behavior recovery
in animal models of PD and in PD patients (Cunningham
et al., 1994; Rosenblad et al., 1996; Yurek et al., 1996,
2009; Sautter et al., 1998; Torres et al., 2005; Emborg
et al., 2008; Andereggen et al., 2009; Somoza et al., 2010;
Deng et al., 2013). Hence, it is tempting to speculate that
Nogo-A neutralization exerts its action not only through
disinhibition of neurite outgrowth but also indirectly through
elevation of neurotrophic factor signaling. Such assumptions,
however, have yet to be proven in the context of cell
transplantation approaches for PD and remain currently
speculative.
CONCLUSION
Taken together, the present report demonstrates that the
continuous delivery of Nogo-A neutralizing antibodies improves
dopaminergic graft function likely by increasing sprouting
of grafted dopaminergic neurons into the host brain. Our
findings support the view that neutralization of Nogo-A
in the host brain may offer a novel and therapeutically
meaningful intervention for cell transplantation approaches in
PD. Further studies, however, will be necessary to evaluate
the clinical potential of this mode of intracerebral delivery
of anti-Nogo-A antibodies to support graft survival and
function.
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